Thromboembolic Events
7
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty.
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation
Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems
Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device